Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 13, 2026

New DDN Report Reveals 65% of Organizations Are Struggling to Achieve AI Success

View original at finance.yahoo.com
New DDN Report Reveals 65% of Organizations Are Struggling to Achieve AI Success 600 business and IT decision-makers reveal in "The 2026 AI Infrastructure Report" that unified platforms, cloud strategies, energy expertise, and partnerships are the key to unlocking real AI success CHATSWORTH, Calif., January 13, 2026--(…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 76% of leaders face fundamental data challenges, from legacy infrastructure and siloed datasets

    80% confidence
  • 97% of organizations overwhelmingly agree that cloud infrastructure is essential to scaling AI

    80% confidence
  • DDN enables up to 70% reduction in power and cooling costs by keeping GPUs fully saturated and moving data in parallel

    80% confidence
  • 98% of organizations cite a skills shortage in both IT and data science roles as a major barrier to scaling AI

    80% confidence
  • AI workloads are projected to grow 110% in the next year

    80% confidence
  • More than half of respondents cite cloud as their fastest path to production

    80% confidence
  • Scaling AI is an integration problem, not a compute problem

    80% confidence
  • 83% of organizations say their internal teams are struggling with AI workloads today

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com